Perinatal Selective Serotonin Reuptake Inhibitor Exposure: Impact on Brain Development and Neural Plasticity.

[en] Selective serotonin reuptake inhibitor (SSRI) medications are the most common antidepressant treatment used during pregnancy and the postpartum period. Up to 10% of pregnant women are prescribed SSRIs. Serotonin plays an integral part in neurodevelopment, and questions have been raised about the placental transfer of SSRIs and the effects of preventing reuptake of presynaptic serotonin on fetal neurodevelopment. Preclinical data is beginning to document a role of early exposure to SSRIs in long-term developmental outcomes related to a number of brain regions, such as the hippocampus, cortex and cerebellum. To date, the majority of preclinical work has investigated the developmental effects of SSRIs in the offspring of healthy mothers; however, more research is needed on the effects of these medications in the face of maternal adversity. This minireview will highlight emerging evidence from clinical and preclinical studies investigating the impact of perinatal SSRI exposure on brain development and neural plasticity.

Disciplines :

Neurology

Author, co-author :

Pawluski, Jodi ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie de la différenciation sexuelle du cerveau

Language :

English

Title :

Perinatal Selective Serotonin Reuptake Inhibitor Exposure: Impact on Brain Development and Neural Plasticity.

Publication date :

2012

Journal title :

Neuroendocrinology

ISSN :

0028-3835

eISSN :

1423-0194

Publisher :

Karger, Basel, Switzerland

Volume :

Issue :

Pages :

39-46

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 12 June 2020

Statistics

Number of views

37 (1 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Pawluski JL, Galea LA: The role of reproductive experience on hippocampal function and plasticity; in Bridges R (ed): Neurobiology of the Parental Brain. Boston, Academic Press, 2008, pp 493-508.
Morrison JL, Riggs KW, Rurak DW: Fluoxetine during pregnancy: impact on fetal development. Reprod Fertil Dev 2005;17:641-650. (Pubitemid 41386845)
Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR: Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;103:698-709. (Pubitemid 40459031)
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898-906. (Pubitemid 44188483)
Huizink AC, de Medina PG, Mulder EJ, Visser GH, Buitelaar JK: Psychological measures of prenatal stress as predictors of infant temperament. J Am Acad Child Adolesc Psychiatry 2002;41:1078-1085. (Pubitemid 38338056)
Glover V, O'Connor TG, O'Donnell K: Prenatal stress and the programming of the hpa axis. Neurosci Biobehav Rev 2010;35:17-22.
Davis EP, Glynn LM, Schetter CD, Hobel C, Chicz-Demet A, Sandman CA: Prenatal exposure to maternal depression and cortisol influences infant temperament. J Am Acad Child Adolesc Psychiatry 2007;46:737-746. (Pubitemid 46816827)
Fleschler R, Peskin MF: Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: a review. MCN Am J Matern Child Nurs 2008;33:355-361; quiz 362-353.
Cooper WO, Willy ME, Pont SJ, Ray WA: Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196:544.e1-e5.
Homberg JR, Schubert D, Gaspar P: New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 2010;31:60-65.
Oberlander TF, Gingrich JA, Ansorge MS: Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 2009;86:672-677.
Lucki I: The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998;44:151-162.
Di Pino G, Moessner R, Lesch KP, Lauder JM, Persico AM: Roles for serotonin in neurodevelopment: more than just neural transmission. Curr Neuropharmacol 2004;2:403-417. (Pubitemid 39276632)
Robbins TW, Granon S, Muir JL, Durantou F, Harrison A, Everitt BJ: Neural systems underlying arousal and attention: implications for drug abuse. Ann N Y Acad Sci 1998;846:222-237.
Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM: Serotonin as a developmental signal. Behav Brain Res 1996;73:19-29. (Pubitemid 26008758)
Whitaker-Azmitia PM, Peroutka SJ: The Neuropharmacology of Serotonin. New York, New York Academy of Sciences, 1990.
Huizink AC, Mulder EJ, Buitelaar JK: Prenatal stress and risk for psychopathology: specific effects or induction of general susceptibility? Psychol Bull 2004;130:115-142. (Pubitemid 38077665)
Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-2383. (Pubitemid 40676760)
Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sorensen HT: Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701-704. (Pubitemid 44655607)
Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-587. (Pubitemid 43209105)
Laine K, Heikkinen T, Ekblad U, Kero P: Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003;60:720-726. (Pubitemid 36818634)
Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W: Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005;115:411-425. (Pubitemid 43193826)
Whitaker-Azmitia PM: Serotonin and brain development: role in human developmental diseases. Brain Res Bull 2001;56:479-485.
Pawluski JL, Galea LA, Brain U, Papsdorf M, Oberlander TF: Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors. Pediatrics 2009;124:e662-e670.
Devlin AM, Brain U, Austin J, Oberlander TF: Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS ONE 2010;5:e12201.
Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Bazarian JJ, Janigro D: Extracranial sources of S100B do not affect serum levels. PLoS One 2010;5:e12691
Whitaker-Azmitia PM, Murphy R, Azmitia EC: Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990;528:155-158. (Pubitemid 20292953)
Haring JH, Hagan A, Olson J, Rodgers B: Hippocampal serotonin levels influence the expression of S100 beta detected by immunocytochemistry. Brain Res 1993;631:119-123. (Pubitemid 23351495)
Manev H, Manev R: Nomen est omen: do antidepressants increase p11 or S100A10? J Biomed Discov Collab 2006;1:5.
Bhattacharyya A, Oppenheim RW, Prevette D, Moore BW, Brackenbury R, Ratner N: S100 is present in developing chicken neurons and Schwann cells and promotes motor neuron survival in vivo. J Neurobiol 1992;23:451-466.
Gonzalez-Martinez T, Perez-Pinera P, Diaz-Esnal B, Vega JA: S-100 proteins in the human peripheral nervous system. Microsc Res Tech 2003;60:633-638.
Selinfreund RH, Barger SW, Pledger WJ, Van Eldik LJ: Neurotrophic protein s100 beta stimulates glial cell proliferation. Proc Natl Acad Sci USA 1991;88:3554-3558. (Pubitemid 21916661)
Branchi I, Francia N, Alleva E: Epigenetic control of neurobehavioural plasticity: the role of neurotrophins. Behav Pharmacol 2004;15:353-362. (Pubitemid 39238345)
Mercier G, Lennon AM, Renouf B, Dessouroux A, Ramauge M, Courtin F, Pierre M: Map kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004;24:207-216. (Pubitemid 41359148)
Karpova NN, Lindholm J, Pruunsild P, Timmusk T, Castren E: Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 2009;19:97-108.
Byrd RA, Markham JK: Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam Appl Toxicol 1994;22:511-518. (Pubitemid 24194714)
Pohland RC, Byrd TK, Hamilton M, Koons JR: Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol 1989;98:198-205. (Pubitemid 19122367)
Borue X, Chen J, Condron BG: Developmental effects of SSRIs: lessons learned from animal studies. Int J Dev Neurosci 2007;25:341-347. (Pubitemid 350051324)
Del Rio J, Montero D, De Ceballos ML: Longlasting changes after perinatal exposure to antidepressants. Prog Brain Res 1988;73:173-187.
Weaver KJ, Paul IA, Lin RC, Simpson KL: Neonatal exposure to citalopram selectively alters the expression of the serotonin transporter in the hippocampus: dose-dependent effects. Anat Rec (Hoboken) 2010;293:1920-1932.
Andrews MH, Matthews SG: Programming of the hypothalamo-pituitary-adrenal axis: serotonergic involvement. Stress 2004;7:15-27. (Pubitemid 38470326)
Romijn HJ, Hofman MA, Gramsbergen A: At what age is the developing cerebral cortex of the rat comparable to that of the full-term newborn human baby? Early Hum Dev 1991;26:61-67.
Swerts CA, Costa AM, Esteves A, Borato CE, Swerts MS: Effects of fluoxetine and imipramine in rat fetuses treated during a critical gestational period: a macro and microscopic study. Rev Bras Psiquiatr 2010;32:152-158.
Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J: A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994;23:194-205. (Pubitemid 24277242)
Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, Paul IA: Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006;31:47-57. (Pubitemid 43250940)
Zusso M, Debetto P, Guidolin D, Barbierato M, Manev H, Giusti P: Fluoxetine-induced proliferation and differentiation of neural progenitor cells isolated from rat postnatal cerebellum. Biochem Pharmacol 2008;76:391-403.
Bairy KL, Madhyastha S, Ashok KP, Bairy I, Malini S: Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2007;79:1-11. (Pubitemid 46034171)
Lisboa SF, Oliveira PE, Costa LC, Venancio EJ, Moreira EG: Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007;80:49-56. (Pubitemid 47013367)
Lee LJ: Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotox Res 2009;15:212-223.
Gentile S: SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 2005;19:623-633.
Xu Y, Sari Y, Zhou FC: Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Brain Res Dev Brain Res 2004;150:151-161. (Pubitemid 38639819)
Weinstock M: The long-term behavioural consequences of prenatal stress. Neurosci Biobehav Rev 2008;32:1073-1086.
O'Mahony SM, Myint AM, van den Hove D, Desbonnet L, Steinbusch H, Leonard BE: Gestational stress leads to depressive-like behavioural and immunological changes in the rat. Neuroimmunomodulation 2006;13:82-88. (Pubitemid 44804600)
Ishiwata H, Shiga T, Okado N: Selective serotonin reuptake inhibitor treatment of early postnatal mice reverses their prenatal stress-induced brain dysfunction. Neuroscience 2005;133:893-901. (Pubitemid 40814597)
Rayen I, Van den Hove D, Prickaerts J, Steinbusch H, Pawluski JL: Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. Accepted. PLoS ONE.
Kendall-Tackett K, Hale TW: The use of antidepressants in pregnant and breastfeeding women: a review of recent studies. J Hum Lact 2010;26:187-195.
Lee HJ, Kim JW, Yim SV, Kim MJ, Kim SA, Kim YJ, Kim CJ, Chung JH: Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol Psychiatry 2001;6:610, 725-728. (Pubitemid 33020593)
Maciag D, Williams L, Coppinger D, Paul IA: Neonatal citalopram exposure produces lasting changes in behavior which are reversed by adult imipramine treatment. Eur J Pharmacol 2006;532:265-269.
Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403-413.
Swerts CA, Costa AM, Esteves A, Borato CE, Swerts MS: Effects of fluoxetine and imipramine in rat fetuses treated during a critical gestational period: a macro and microscopic study. Rev Bras Psiquiatr 2010;32:152-158.